Matthew Andrews
Recent Quotes
"We believe there is ample precedent for European approval fo Qinprezo."
—
Matthew Andrews, Wells Fargo Securities
(11/6/15)
more >
"Of most interest is when SNSS files the Qinprezo MAA in Europe."
—
Matthew Andrews, Wells Fargo Securities
(10/5/15)
more >
"SNSS ended Q2/15 with $39.6M in cash."
—
Matthew Andrews, Wells Fargo Securities
(7/31/15)
more >
"The EMA encouraged SNSS to submit an MAA in R/R AML >60 years."
—
Matthew Andrews, Wells Fargo Securities
(7/24/15)
more >
"FDA and EMA meetings could lead to submissions by SNSS in late summer."
—
Matthew Andrews, Wells Fargo Securities
(6/12/15)
more >
"An overall survival trend favors SNSS' vosaroxin plus cytarabine."
—
Matthew Andrews, Wells Fargo Securities
(5/14/15)
more >
"SNSS' cash on hand at March 31, 2015 was $39.8M."
—
Matthew Andrews, Wells Fargo Securities
(5/6/15)
more >
"SNSS has made progress in a dialog with the FDA related to Qinprezo."
—
Matthew Andrews, Wells Fargo Securities
(3/12/15)
more >
